BPGbio Collaborates with University of Oxford for Research in Oncology and Central Nervous System (CNS) Diseases
Monday, October 07, 2024
BPGbio has entered into a five-year research collaboration with the University of Oxford’s Centre for Medicines Discovery.
The partnership aims to develop novel protein degradation technologies, particularly targeting oncology and central nervous system (CNS) diseases, with the goal of discovering new treatment pathways for conditions with limited therapeutic options.
The collaboration will proceed in stages, beginning with the validation of BPGbio’s E2 TPD technology, followed by further research into the degradable target space.
The objective is to identify new therapeutic targets and produce high-quality scientific publications. This builds on BPGbio’s existing E2-based protein degradation programme, which includes a proprietary library of over 1,000 Ro3 fragments, potentially acting as ligands and seed compounds for various E2 targets.
The collaboration will also make use of BPGbio’s proprietary ternary structures, computational tools for E2 ligand design, and assays to improve the selectivity and specificity of treatments.
It will leverage the expertise of the University of Oxford’s Centre for Medicines Discovery in translational research, particularly in neurological diseases like Parkinson’s Disease.
A key aspect of the collaboration involves BPGbio’s NAi Interrogative Biology® Platform, which integrates patient biology with AI-driven analysis to accelerate biomarker discovery and therapeutic development.
Together, the organisations aim to advance protein degradation science and provide new treatments for cancers and CNS disorders where significant unmet medical needs persist.
Source: bpgbio.com
